Refine by
Disease Development Articles & Analysis
201 news found
Creative BioMart, a biotechnology company focused on protein-related research solutions, has recently upgraded its epitope mapping service to better support researchers in therapeutic antibody development, vaccine design, and immunogenicity studies. The updated platform integrates multiple experimental approaches with customizable strategies, enabling more accurate identification ...
These models—chemically induced, genetically engineered, or diet-induced—have the potential to advance diabetes research by giving scientists the means to support the identification and development of novel treatment approaches. Diabetes mellitus, a chronic condition characterized by elevated blood sugar levels, affects millions worldwide and poses serious health ...
As an expert in providing solutions to assist virology and microbiology research, Creative Diagnostics has announced the launch of its Zika Virus Animal Model services for scientists to understand the complex mechanisms of Zika virus infection and develop effective countermeasures. These models are valuable tools in the research and development of vaccines and ...
Protheragen, a dedicated preclinical research service provider specializing in rare diseases, announces its comprehensive diagnostic development services aimed at empowering researchers in the realm of rare disease research and drug development. ...
Protheragen is proud to release the launch of its comprehensive vaccine development solutions tailored to advance research and development in the field of infectious diseases. ...
Ace Therapeutics is proud to announce the launch of its cardiovascular disease model development services, aiming to empower researchers and pharmaceutical companies with advanced tools and models to accelerate the study of cardiovascular diseases and drug discovery. ...
Regular intake has been demonstrated to reduce symptoms of depression and anxiety, enhance fetal brain development, and lower heart disease risks by managing cholesterol and blood pressure levels. ...
As the scientific community continues to explore the intricate world of epigenetics, MeRIP Sequencing emerges as a powerful tool for deciphering the role of RNA modifications in gene expression, development, and disease. CD Genomics' commitment to advancing epigenomics research through state-of-the-art technologies underscores their dedication to driving ...
Their use is crucial in unraveling the complexities of related diseases and developing effective treatments. By employing appropriate behavioral research methods, scientists can establish a solid foundation for studying these diseases, leading to invaluable insights and potential breakthroughs in patient care. ...
As several gene therapy approvals for rare disease treatment gain steam in 2023, a comprehensive set of gene therapy development solutions is released to pave richer avenues for rare disease research. ...
All these APIs are essential for the development of effective drugs to meet various medical needs. Amino Acid SeriesAmino acids are the building blocks of proteins and are critical for several physiological processes. CD Formulation offers a variety of amino acids and amino acid derivatives, including DL-Alanine (CAS 302-72-7), Glycylglutamine (CAS 13115-71-4), N-Acetyl-L-Leucine ...
This offering provides researchers and clinicians with a powerful tool to investigate the exome, shedding light on the intricacies of the human genome and propelling our understanding of genetic diseases. In the era of precision medicine, comprehensive and precise genetic information plays a pivotal role. ...
Mass spectrometry is a powerful analytical tool that plays a key role in drug development by providing accurate, reliable, and timely data for successful clinical trials, disease research, drug development, and target discovery experiments. ...
Nubeqa is already approved for the treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC), who are at high risk of developing metastatic disease. “Today’s approval of Nubeqa represents a significant milestone in addressing unmet medical needs for people living with metastatic hormone-sensitive prostate cancer in ...
ByBayer AG
Airfinity announces today the launch of Airfinity IDA (Infectious Disease Analytics) 360, a new platform that will provide a comprehensive overview of vaccine and therapeutics candidates across the full infectious disease landscape. Airfinity IDA 360, a first-of-its-kind product in the health analytics market, will be a centralised source of competitive ...
High demand seen for effective disease management platform for second most common cancer in Singaporean men NEW YORK and SINGAPORE, March 28, 2022 /PRNewswire/ -- miR Scientific, a New York-based healthcare company dedicated to transforming global cancer management, and Leonie Hill Capital, a Singapore-based organization focused on large-scale, sophisticated healthcare access and distribution, ...
This service intuitively studies the relationship between gut flora and disease development, providing new ideas for disease prevention and treatment and improving host health. ...
Darolutamide is already approved under the brand name Nubeqa™ for the treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC), who are at high risk of developing metastatic disease. “This positive CHMP opinion underscores darolutamide’s potential to set a new standard of care for eligible patients living with ...
ByBayer AG
Phase 1 trial of tau-targeting lead program planned to begin in 3Q22 Funding will also support the characterization of the Company’s second-generation assets Oligomerix, Inc., a privately held company pioneering the development of small molecule therapeutics targeting tau for rare neurodegenerative and Alzheimer’s diseases, announced that the ...
Oligomerix, Inc., a privately held company pioneering the development of small molecule therapeutics targeting tau for Alzheimer’s and rare neurodegenerative diseases, announced that the Company presented data from a therapeutic study in an animal model of its lead product candidate OLX-07010 at the 14th Annual Clinical Trials on Alzheimer's ...